Skip to content

Tenofovir / FTC 'non-inferior' to Combivir after one year, Gilead study shows (corrected)

Boosted saquinavir monotherapy explored as treatment option for patients with advanced HIV in South Africa

Substantial, but imperfect adherence a major risk factor for resistance amongst patients starting HAART

Rash no more frequent in Thais treated with NNRTIs than Caucasians

High incidence of IRIS amongst HIV-positive TB patients starting HAART in India

Risk factors for immune reaction to HAART in TB patients studied by French

A case for earlier initiation of HAART, or still a need for caution?

Truvada receives scientific approval in Europe

Early virologic failure with ddI/tenofovir plus nevirapine or efavirenz